Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

t sales.

Research and development costs for the full year 2012 were $45.9 million compared with $61.9 million for the full year 2011.  This decrease in expense results principally from a reduction in 2012 of activities related to the development of a larger scale XIAFLEX production process and the completion of the phase III XIAFLEX clinical trials for Peyronie's disease in third quarter 2012, partially offset by spending in 2012 related to the Dupuytren's multi-cord study and new indications for XIAFLEX.

Selling, general and administrative expenses totaled $185.5 million for the year ended December 31, 2012, compared with $179.9 million for the year-ago period.  This increase was primarily due to marketing spending for Dupuytren's and for the potential future launch of Peyronie's, increased business development and legal expenses, and costs incurred in 2012 related to the relocation of the company's headquarters, offset in part by costs incurred in 2011 related to management changes.

Auxilium reported net income of $85.9 million, or $1.74 per share, fully diluted, for the full year 2012, compared to a net loss of $(32.9) million, or $(0.69) per share, fully diluted, for the full year 2011.  The increase in net income was primarily related to $85.2 million recorded as a result of the previously announced agreement to mutually terminate the Company's European collaboration with Pfizer.  Net income for 2012 includes total stock-based compensation expense of $15.0 million, compared to $17.3 million included in the net loss for the full year 2011.

Accounting for Pfizer TerminationAs part of the collaboration agreement we entered into with Pfizer in 2008, we have received up front and milestone cash payments from Pfizer.  Our agreement with our licensor for XIAFLEX required that we pay a portion of these amounts to them.  These amounts were recorded as deferred revenues and deferred costs, respectively, on our b
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
(Date:5/28/2015)... May 28, 2015 BioNorth Texas ... and representing the life sciences industry in northern ... Directors meeting at The Foundry in Dallas on ... organization brought together a broad spectrum of biotech ... the organization's early successes in partnering with key ...
(Date:5/28/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: RXII ... innovative therapeutics, primarily in the areas of dermatology and ... of 26 million units at a price to the ... approximately $10.4 million. Each unit consists of (i) one ... right to purchase 0.50 of a share of common ...
(Date:5/28/2015)... 28, 2015  GenVec, Inc. (Nasdaq: GNVC ) ... J. Swirsky , will present a company overview at ... EDT on Thursday, June 4, 2015. ... will be available at the following link:  http://wsw.com/webcast/jeff88/gnvc ... website.  To access, visit www.genvec.com , click on ...
Breaking Biology Technology:First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2
... N.C. , May 13 Chimerix, Inc., ... the commencement of a first-in-human study of CMX157, a ... in vitro activity against both tenofovir-sensitive and tenofovir-resistant ... increase efficacy and decrease toxicity as compared to tenofovir, ...
... LA JOLLA, Calif. , May 13 Transdel ... focused on developing topically administered products using its proprietary transdermal ... March 31, 2010 .  The Company also highlighted recent ... , ...
... , DUBLIN and PHILADELPHIA , ... ), the global specialty biopharmaceutical company,announces that its subsidiary Shire LLC has ... Delaware against Actavis Elizabeth LLC and,Actavis Inc. (collectively "Actavis") for the ... and 6,811,794,(the ,794 patent). , , ...
Cached Biology Technology:Chimerix Initiates Phase 1 Study of CMX157 2Chimerix Initiates Phase 1 Study of CMX157 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 2Transdel Pharmaceuticals Reports First Quarter 2010 Results 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 4Transdel Pharmaceuticals Reports First Quarter 2010 Results 5INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 2INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 3
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/14/2015)... DUBLIN , May 14, 2015 Research and ... addition of the "Fingerprint Sensors Market in Smart ... This report believes that 2014 was a watershed ... to Apple,s introduction of ,Apple Pay,. Apple gave fingerprint ... its mobile payment service. Fingerprint sensors are a must-have ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... ants may not sound like a cool thing, but wait ... On April 29, on the grounds of the Texas AgriLife ... Scott Ludwig released fire ants infected with a new type ... red imported fire ants. The infected ants will soon ...
... of H1N1 swine flu have been investigated in a ... access Virology Journal studied the pathology of ... symptoms between one and four days after infection and ... Thanawongnuwech led a team of researchers from Chulalongkorn University, ...
... (DMD) for 2 years before they obtain a ... delay children have endured for the past 20 years ... and inexpensive blood test for any boy with symptoms ... up the process while pilot studies on newborn screening ...
Cached Biology News:New phorid fly species turns red imported fire ants into 'zombies' 2Muscular dystrophy diagnosis delayed almost 2.5 years in boys 2
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
BD BioCoat Laminin 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... Ciphergens ProteinChip System, Series 4000 incorporates the ... researchers and biologists in biomarker research. The ... fastest route for converting biomarker discoveries to ... The Series 4000 is designed to fit ...
MHC II (HLA-DP)...
Biology Products: